Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

“Diseases are becoming more precisely defined; in small populations and rare diseases, RCTs are unlikely to be the most efficient way to get innovative products to patients. @OUPAcademic describes one model being tried in the Netherlands in cancer.”